By Pranav Kashyap and Twesha Dikshit Feb 4 (Reuters) - The S&P 500 and the Dow were poised for a firmer open on Wednesday, ...

In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a +1.27% move from the preceding trading day.

Lilly agrees to acquire Orna Therapeutics in an all-cash deal.

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine ...

In the latest trading session, Eli Lilly (LLY) closed at $1,064.29, marking a -2.12% move from the previous day. This change ...

Market confidence amid sustained momentum, shifting sector leadership, and expectations of continued gains have helped the ...

Polen Capital Management Llc released its “Polen Focus Growth Strategy” Q4 2025 investor letter. A copy of the letter can be ...

Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised its quarterly dividend 15% to $1.73 per share. The ...

Pfizer is playing catch-up in the GLP-1 space, but it has a long history of innovation.

Wall Street is coming off a major sell-off in software stocks that drove the S&P 500 to a second straight day of losses.